Related Experiment Videos
A 5-year retrospective analysis of alpha-interferon usage.
1West Los Angeles Medical Center, CA 90073, USA.
Hospital Pharmacy
|August 1, 1995
Summary
Alpha interferon showed moderate effectiveness in treating certain hematologic malignancies, with notable responses in Hairy cell leukemia and chronic myelogenous leukemia. However, patient intolerance limited its widespread clinical application.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Alpha interferon is an immune modulator with established FDA-approved uses in hematologic malignancies and immunosuppressive diseases.
- Ongoing research explores novel clinical applications for interferon therapy.
- Evaluating institutional data is crucial for understanding real-world efficacy and safety.
Purpose of the Study:
- To assess the appropriateness, efficacy, and safety of alpha interferon therapy.
- To compare institutional response rates with published literature.
- To identify key factors influencing interferon treatment outcomes.
Main Methods:
- Retrospective chart review of patients treated with alpha interferon between 1987 and 1991.
- Analysis of patient demographics, diagnoses, treatment responses, and adverse events.
- Comparison of observed response rates against established literature values.
Main Results:
- Twenty-six patients received alpha interferon; 38% (10 patients) showed a partial response.
- Highest response rates were observed in Hairy cell leukemia (67%) and chronic myelogenous leukemia (57%).
- Intolerance affected 46% (12 patients), with only 19% (5 patients) remaining on therapy long-term.
Conclusions:
- Alpha interferon demonstrates moderate efficacy in specific hematologic malignancies.
- Patient intolerance is a significant barrier to the sustained clinical use of alpha interferon.
- Further research may focus on managing side effects to improve therapeutic outcomes.